Diagnostic biomarkers in Alzheimer’s disease
Authors:
- Emerlee AndersenEAEmerlee Andersen
- Bryce CasteigneBCBryce Casteigne
- William Daniel ChapmanWCWilliam Daniel Chapman
- Andrew CreedACAndrew Creed
- Forrest FosterFFForrest Foster
- Allison LapinsALAllison Lapins
- Rhonna ShatzRSRhonna Shatz
- Russell P. SawyerRSRussell P. Sawyer
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Biomarkers in Neuropsychiatry
- Vol. 5
Abstract
No abstract availableKeywords
This publication has 135 references indexed in Scilit:
- Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologiesNature Reviews Neuroscience, 2013
- Regulatory Innovation and Drug Development for Early-Stage Alzheimer's DiseaseNew England Journal of Medicine, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's diseaseBrain, 2010
- Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrationsNature Biotechnology, 2010
- Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burdenBrain, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface areaNeurobiology of Aging, 2009
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseBrain, 2008